2023/09/29 17:36:41 | |
---|---|
Price | |
0.387 EUR | |
Difference | 7.50% (0.03) |
ISIN | FR0012432516 |
Symbol | POXEL |
Exchange | Euronext Paris |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 14 EUR |
Benchmark | CAC 40 INDEX |
Bid (Bid size) | 0.3555 EUR (2,000) |
Ask (Ask size) | 0.389 EUR (5,000) |
Open | 0.3725 EUR |
High | 0.387 EUR |
Low | 0.35 EUR |
Close (prev. day) | 0.36 EUR |
VWAP | 0.367524 EUR |
Volume (pcs) | 234,637 |
Trading volume | 86,235.00 |
Number of trades | 168 |
Last size | 1,656 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2023/09/29 |
![]() |
Global Equity Ratings |
![]() |
2023/09/29 |
![]() |
Aktienempfehlungen Global |
![]() |
2023/09/22 |
![]() |
Equity Weekly |
![]() |
2023/09/18 |
![]() |
Aktienempfehlungen Österreich |
![]() |
2023/09/18 |
![]() |
Equity Weekly |
![]() |
2023/09/29 17:36:41 | |
---|---|
Price | |
0.387 EUR | |
Difference | 7.50% (0.03) |
ISIN | FR0012432516 |
Symbol | POXEL |
Exchange | Euronext Paris |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 14 EUR |
Benchmark | CAC 40 INDEX |
Bid (Bid size) | 0.3555 EUR (2,000) |
Ask (Ask size) | 0.389 EUR (5,000) |
Open | 0.3725 EUR |
High | 0.387 EUR |
Low | 0.35 EUR |
Close (prev. day) | 0.36 EUR |
VWAP | 0.367524 EUR |
Volume (pcs) | 234,637 |
Trading volume | 86,235.00 |
Number of trades | 168 |
Last size | 1,656 |
6M | 1Y | 3Y | |
Perf (%) | -44.71% | -75.51% | -94.21% |
Perf (abs.) | -0.31 | -1.19 | -6.29 |
Beta | 1.04 | 0.75 | 0.94 |
Volatility | 61.14 | 59.73 | 55.98 |
Ø price 5 days | Ø volume 5 days (pcs.) | 0.411 EUR (223,002) |
Ø price 30 days | Ø volume 30 days (pcs.) | 0.538 EUR (157,511) |
Ø price 100 days | Ø volume 100 days (pcs.) | 0.604 EUR (132,603) |
Ø price 250 days | Ø volume 250 days (pcs.) | 0.841 EUR (102,078) |
YTD High | date | 1.080 EUR (2023/01/25) |
YTD Low | date | 0.350 EUR (2023/09/29) |
52 Weeks High | date | 1.628 EUR (2022/10/03) |
52 Weeks Low | date | 0.350 EUR (2023/09/29) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Berlin | 2023/09/29 | 08:06 | 0.321 EUR | 0.00 | 1 |
Euronext Paris | 2023/09/29 | 17:36 | 0.387 EUR | 0.09 | 168 |
FINRA other OTC Issues | 2023/08/08 | 18:22 | 0.60 USD | 0.00 | 1 |
Frankfurt | 2023/09/29 | 17:20 | 0.34 EUR | 0.00 | 5 |
London Stock Exchange European Trade Reporting | 2023/09/29 | 17:30 | 0.3772 EUR | 0.00 | 2 |
Munich | 2023/09/29 | 08:05 | 0.401 EUR | 0.00 | 1 |
Stuttgart | 2023/09/29 | 16:43 | 0.368 EUR | 0.00 | 12 |
POXEL SA |
- - |
259/261, Avenue Jean Jaurès - 69007 Lyon |
Telefon: +33-4-37-37-20-12 |
Fax: +33-4-37-70-88-15 |
E-mail: - |
Poxel SA operates as a clinical-stage biopharmaceutical company. The firm focuses on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as non-alcoholic steatohepatitis (NASH). Its drug candidates include Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH. The company was founded by Sébastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres, and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France. |
Mohammed Khoso Baluch | Chairman of Supervisory Board |
Pascale Boissel | Member of Supervisory Board |
Richard Kender | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).
The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.
Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended). For this reason, the distribution or redistribution of the information, materials and products into United States or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited. The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.
The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.
By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.